Roche to close Nutley, USA, site with 1,000 job losses
Swiss drug major Roche (ROG: SIX) yesterday announced a consolidation and streamlining of research activities, that will see the closing of what was for more than 80 years its US headquarters in Nutley, New Jersey, with R&D activities there to be consolidated in Switzerland (Schlieren) and Germany (Penzberg), focusing on oncology, virology, metabolism and neuroscience.
Closure of the Nutley site will result in a reduction of around 1,000 jobs. The move is another indication of difficulties in the pharmaceutical industry, which is currently facing the biggest “patent cliff” in history, with the likes of Pfizer and AstraZeneca having already announced thousands of job losses in their R&D and other operations.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
| Headless Content Management with Blaze